Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lagercrantz Group AB in connection with its acquisition of Prido AB
Mandate

Vinge advises Lagercrantz Group AB in connection with its acquisition of Prido AB

February 07, 2024 Employment and Benefits Capital Markets and Public M&A IT, Telecommunications and Outsourcing Intellectual Property Data protection and processing of personal data Real Estate and Construction EU, Competition and Regulatory

Vinge advises Lagercrantz Group AB in connection with its acquisition of 96% of the shares in Prido AB. Prido AB was founded in 1973 and is today one of Europe's largest manufacturers of high-quality industrial folding doors, with an annual revenue of approximately SEK 300 million. The transaction is subject to approval by the relevant authorities and is expected to close in March 2024.

Vinge's team consisted of Johan Winnerblad, Clara Sohlberg and Filip Magnusson (M&A), Victor Björkheim (Employment), Ellis Allmark (Agreements), Sofia Bergenståhle (IPR), Johan Cederblad, Karolina Cohrs and Madelene Andersson (Real Estate and environment), Ida Redander (Finance), Alva Chambert (Competition) and Arthur Kinski (IT/GDPR).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026